Printer Friendly

COMPANY INFORMATION
iCo Therapeutics Inc. 760-777 Hornby St Vancouver, BC V6Z 1S4 Tel: (604) 602-9414 Fax: (604) 602-9699 Contact Name W. John Meekison Industry Biotechnology		Key Executives Andrew J. Rae, CEO W. John Meekison, CFO Develops drug candidates to treat sight threatening diseases such as diabetic retinopathy and allergic conjunctivitis as well as life threatening diseases.
FP ADVISOR COVERAGE iCo Therapeutics Inc. • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/ICO $0.45 $0.80 $0.11 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 11,258 n.a. $-0.09 Sept. 30/09 125.0% 3.49% n.a. $17,167
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 $000s $000s $000s Net income (2,742) (5,187) (2,540) Total assets 1,466 3,279 2,647 $ $ $ Earnings per share* (0.14) (0.41) (0.78) % % % Return on equity (155.88) (235.56) (182.67)   * Common

COMPANY NEWS

Results for 'iCo Therapeutics Inc.' from past 30 days: No hits. (Links are to articles.)